Related references
Note: Only part of the references are listed.Outcomes of persons with blastomycosis involving the central nervous system
Jonathan W. Bush et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2013)
Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group
Gertjan J. L. Kaspers et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis
John W. Baddley et al.
MEDICAL MYCOLOGY (2013)
Risk stratification for invasive aspergillosis in immunocompromised patients
Raoul Herbrecht et al.
ADVANCES AGAINST ASPERGILLOSIS I (2012)
Differences in Efficacy and Cytokine Profiles following Echinocandin or Liposomal Amphotericin B Monotherapy or Combination Therapy for Murine Pulmonary or Systemic Aspergillus flavus Infections
J. A. Olson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Experimental Central Nervous System Aspergillosis Therapy: Efficacy, Drug Levels and Localization, Immunohistopathology, and Toxicity.
Karl V. Clemons et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma
Nicola Goekbuget et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis
Karl V. Clemons et al.
MEDICAL MYCOLOGY (2011)
An Evaluation of Hepatotoxicity and Nephrotoxicity of Liposomal Amphotericin B (L-AMB)
Gourang P. Patel et al.
JOURNAL OF MEDICAL TOXICOLOGY (2011)
Liposomal Amphotericin B and Echinocandins as Monotherapy or Sequential or Concomitant Therapy in Murine Disseminated and Pulmonary Aspergillus fumigatus Infections
Jon A. Olson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B (AmBisome)
Akira Watanabe et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2010)
Pulmonary Epithelial Lining Fluid Concentrations after Use of Systemic Amphotericin B Lipid Formulations
Stefan Weiler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Efficacy and Safety of Liposomal Cytarabine in Lymphoma Patients With Central Nervous System Involvement From Lymphoma
Jose A. Garcia-Marco et al.
CANCER (2009)
Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B
Bertrand F. Dupont et al.
CRITICAL CARE (2009)
Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2008)
Amphotericin B formulations and drug targeting
J. J. Torrado et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products
Jon A. Olson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis
Russell E. Lewis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations
Andreas H. Groll et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model
Jon A. Olson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Cytokines and fungal infections
C Antachopoulos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients
CB Miller et al.
BONE MARROW TRANSPLANTATION (2004)
Comparative efficacies of four amphotericin B formulations - Fungizone, amphotec (Amphocil), AmBisome, and Abelcet - against systemic murine aspergillosis
KV Clemons et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Novel inhalational murine model of invasive pulmonmy aspergillosis
DC Sheppard et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Susceptibility patterns of bacteria causing community-acquired respiratory infections in Spain:: the SAUCE project
J García-de-Lomas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2002)
Effects of membrane partitioning and other physical chemical properties on the apparent potency of membrane active compounds evaluated using red blood cell lysis assays
D Chapman et al.
ANALYTICAL BIOCHEMISTRY (2002)
Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans
I Bekersky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole
LJ Wheat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Pulmonary extraction and accumulation of lipid formulations of amphotericin B
I Matot et al.
CRITICAL CARE MEDICINE (2000)
Share Paper
